Arcellx Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
220
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.45B
Arcellx General Information
Description
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Contact Information
Website
www.arcellx.comCorporate Office
- 800 Bridge Parkway
- Suite A
- Redwood City, CA 94065
- United States
Corporate Office
- 800 Bridge Parkway
- Suite A
- Redwood City, CA 94065
- United States
Arcellx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 28-Apr-2026 | $6.45B | Completed | Generating Revenue | ||
| 7. PIPE | 15-Dec-2023 | Completed | Generating Revenue | |||
| 6. 2PO | 15-Jun-2022 | Completed | Generating Revenue | |||
| 5. PIPE | 04-Mar-2022 | Completed | Generating Revenue | |||
| 4. IPO | 04-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series C) | 09-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 14-Oct-2019 | $85M | $114M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 17-Jan-2017 | $29M | $29M | Completed | Pre-Clinical Trials |
Arcellx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B-2 | ||||||||
| Series B-1 | 27,444,339 | $0.001000 | 8% | $1.56 | $1.56 | 1x | $1.56 | 15.77% |
| Series A | 29,795,227 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 17.12% |
Arcellx Comparisons
Industry
Financing
Details
Arcellx Competitors (17)
One of Arcellx’s 17 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA | ||||
| AbelZeta | Venture Capital-Backed | Rockville, MD | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
Arcellx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arcellx Patents
Arcellx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026232010-A1 | Cd33-binding domains and methods of use | Pending | 02-May-2025 | ||
| WO-2026136173-A1 | And-gated chimeric antigen receptors comprising kinase domains | Pending | 16-Dec-2024 | ||
| AU-2023406036-A1 | D-domain containing polypeptides and uses thereof | Pending | 29-Nov-2022 | ||
| EP-4626912-A2 | D-domain containing polypeptides and uses thereof | Pending | 29-Nov-2022 | ||
| US-20250353908-A1 | D-domain containing polypeptides and uses thereof | Pending | 29-Nov-2022 | C07K16/2803 |
Arcellx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Arcellx Former Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CAM Capital | Asset Manager | Minority | ||
| CaaS Capital Management | Hedge Fund | Minority | ||
| Cambrian Bio | VC-Backed Company | Minority | ||
| Clough Capital Partners | Hedge Fund | Minority | ||
| JVC Investment Partners | Family Office | Minority |
Arcellx ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Arcellx FAQs
-
When was Arcellx founded?
Arcellx was founded in 2014.
-
Where is Arcellx headquartered?
Arcellx is headquartered in Redwood City, CA.
-
What is the size of Arcellx?
Arcellx has 220 total employees.
-
What industry is Arcellx in?
Arcellx’s primary industry is Drug Discovery.
-
Is Arcellx a private or public company?
Arcellx is a Private company.
-
What is the current valuation of Arcellx?
The current valuation of Arcellx is .
-
What is Arcellx’s current revenue?
The current revenue for Arcellx is .
-
How much funding has Arcellx raised over time?
Arcellx has raised $760M.
-
Who are Arcellx’s investors?
CAM Capital, CaaS Capital Management, Cambrian Bio, Clough Capital Partners, and JVC Investment Partners are 5 of 23 investors who have invested in Arcellx.
-
Who are Arcellx’s competitors?
Allogene Therapeutics, Senti Biosciences Holdings, AbelZeta, Caribou Biosciences, and Poseida Therapeutics are some of the 17 competitors of Arcellx.
-
When was Arcellx acquired?
Arcellx was acquired on 28-Apr-2026.
-
Who acquired Arcellx?
Arcellx was acquired by Gilead.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
